263 related articles for article (PubMed ID: 31817853)
1. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
2. Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia.
Polak R; Bierings MB; van der Leije CS; Sanders MA; Roovers O; Marchante JRM; Boer JM; Cornelissen JJ; Pieters R; den Boer ML; Buitenhuis M
Haematologica; 2019 Apr; 104(4):738-748. PubMed ID: 30381299
[TBL] [Abstract][Full Text] [Related]
3. Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.
Sender S; Sekora A; Villa Perez S; Chabanovska O; Becker A; Ngezahayo A; Junghanss C; Murua Escobar H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435587
[TBL] [Abstract][Full Text] [Related]
4. ETV6-RUNX1 interacts with a region in SPIB intron 1 to regulate gene expression in pre-B-cell acute lymphoblastic leukemia.
Xu LS; Francis A; Turkistany S; Shukla D; Wong A; Batista CR; DeKoter RP
Exp Hematol; 2019 May; 73():50-63.e2. PubMed ID: 30986496
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I; Imamura T; Takahashi Y; Suenobu SI; Hasegawa D; Hashii Y; Deguchi T; Hori T; Shimada A; Kato K; Ito E; Moriya-Saito A; Kawasaki H; Hori H; Yumura-Yagi K; Hara J; Sato A; Horibe K;
Int J Hematol; 2019 Apr; 109(4):477-482. PubMed ID: 30689137
[TBL] [Abstract][Full Text] [Related]
6. RAG1 co-expression signature identifies ETV6-RUNX1-like B-cell precursor acute lymphoblastic leukemia in children.
Chen D; Camponeschi A; Nordlund J; Marincevic-Zuniga Y; Abrahamsson J; Lönnerholm G; Fogelstrand L; Mårtensson IL
Cancer Med; 2021 Jun; 10(12):3997-4003. PubMed ID: 33987955
[TBL] [Abstract][Full Text] [Related]
7. Infection Exposure Promotes
Rodríguez-Hernández G; Hauer J; Martín-Lorenzo A; Schäfer D; Bartenhagen C; García-Ramírez I; Auer F; González-Herrero I; Ruiz-Roca L; Gombert M; Okpanyi V; Fischer U; Chen C; Dugas M; Bhatia S; Linka RM; Garcia-Suquia M; Rascón-Trincado MV; Garcia-Sanchez A; Blanco O; García-Cenador MB; García-Criado FJ; Cobaleda C; Alonso-López D; De Las Rivas J; Müschen M; Vicente-Dueñas C; Sánchez-García I; Borkhardt A
Cancer Res; 2017 Aug; 77(16):4365-4377. PubMed ID: 28630052
[No Abstract] [Full Text] [Related]
8. Outcome and Prognostic Factors for
Lee JW; Kim SK; Jang PS; Chung NG; Jeong DC; Kim M; Cho B; Kim HK
Cancer Res Treat; 2017 Apr; 49(2):446-453. PubMed ID: 27506214
[TBL] [Abstract][Full Text] [Related]
9. Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol.
Gandemer V; Chevret S; Petit A; Vermylen C; Leblanc T; Michel G; Schmitt C; Lejars O; Schneider P; Demeocq F; Bader-Meunier B; Bernaudin F; Perel Y; Auclerc MF; Cayuela JM; Leverger G; Baruchel A;
Haematologica; 2012 Nov; 97(11):1743-50. PubMed ID: 22580999
[TBL] [Abstract][Full Text] [Related]
10. High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.
Hoffmann J; Krumbholz M; Gutiérrez HP; Fillies M; Szymansky A; Bleckmann K; Zur Stadt U; Köhler R; Kuiper RP; Horstmann M; von Stackelberg A; Eckert C; Metzler M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27780. PubMed ID: 31034759
[TBL] [Abstract][Full Text] [Related]
11. Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.
Bokemeyer A; Eckert C; Meyr F; Koerner G; von Stackelberg A; Ullmann R; Türkmen S; Henze G; Seeger K
Haematologica; 2014 Apr; 99(4):706-14. PubMed ID: 24241490
[TBL] [Abstract][Full Text] [Related]
12. Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.
Ghazavi F; De Moerloose B; Van Loocke W; Wallaert A; Helsmoortel HH; Ferster A; Bakkus M; Plat G; Delabesse E; Uyttebroeck A; Van Nieuwerburgh F; Deforce D; Van Roy N; Speleman F; Benoit Y; Lammens T; Van Vlierberghe P
Oncotarget; 2016 Nov; 7(45):73769-73780. PubMed ID: 27650541
[TBL] [Abstract][Full Text] [Related]
13. The Landscape of Secondary Genetic Rearrangements in Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia with t(12;21).
Kaczmarska A; Derebas J; Pinkosz M; Niedźwiecki M; Lejman M
Cells; 2023 Jan; 12(3):. PubMed ID: 36766699
[TBL] [Abstract][Full Text] [Related]
14. Investigation of lncRNA-mRNA co-expression network in ETV6-RUNX1-positive pediatric B-cell acute lymphoblastic leukemia.
Yu W; Wang W; Yu X
PLoS One; 2021; 16(6):e0253012. PubMed ID: 34101758
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of ETV6/RUNX1 and MLL aberrations in B-cell precursor acute lymphoblastic leukemia discloses a small subclass of BCP-ALL.
Amare Kadam PS; Raje GC; Pais AP; Banavali S
Cancer Genet Cytogenet; 2008 Apr; 182(1):27-32. PubMed ID: 18328947
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and prognostic factors of the chemotherapy regimen of CCLG-ALL-2008 on pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement].
Liu F; Chen XJ; Guo Y; Yang WY; Chen X; Zhang XY; Zhang RR; Ren YY; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):896-902. PubMed ID: 33333691
[No Abstract] [Full Text] [Related]
17. Low Frequency of ETV6-RUNX1 (t 12; 21) in Saudi Arabian Pediatric Acute Lymphoblastic Leukemia Patients: Association with Clinical Parameters and Early Remission.
Aljamaan K; Aljumah TK; Aloraibi S; Absar M; Iqbal Z
Asian Pac J Cancer Prev; 2015; 16(17):7523-7. PubMed ID: 26625756
[TBL] [Abstract][Full Text] [Related]
18. The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.
Colado A; Almejún MB; Podaza E; Risnik D; Stanganelli C; Elías EE; Dos Santos P; Slavutsky I; Fernández Grecco H; Cabrejo M; Bezares RF; Giordano M; Gamberale R; Borge M
Cancer Immunol Immunother; 2017 Apr; 66(4):461-473. PubMed ID: 28011996
[TBL] [Abstract][Full Text] [Related]
19. Analysis of ETV6/RUNX1 fusions for evaluating the late effects of cancer therapy in ALL (acute lymphoblastic leukemia) cured patients.
Brassesco MS; Camparoto ML; Tone LG; Sakamoto-Hojo ET
Cytogenet Genome Res; 2004; 104(1-4):346-51. PubMed ID: 15162063
[TBL] [Abstract][Full Text] [Related]
20. Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing.
Jin Y; Wang X; Hu S; Tang J; Li B; Chai Y
Cancer Med; 2016 Feb; 5(2):337-51. PubMed ID: 26711002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
